TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19038899

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 or 400 mg daily)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 15794777

Group type: EXPERIMENTAL
Intervention: Bladder neck mucosal eversion
Number of subjects: 100

Group type: COMPARATOR
Intervention: No bladder neck mucosal eversion
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early urinary extravasation
Number of subjects: 100
Study: 14627476

Group type: EXPERIMENTAL
Intervention: Lap-Band system (INAMED)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heliogast band (Hélioscopie)
Number of subjects: 60
Study: 10871568

Group type: EXPERIMENTAL
Intervention: Carb + Pro trial (0.8 g carbohydrate*kg(‐)(1)*h(‐)(1) plus 0.4 g wheat protein hydrolysate plus free leucine and phenylalanine*kg(‐)(1)*h(‐)(1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carb + Carb trial (1.2 g carbohydrate*kg(‐)(1)*h(‐)(1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carb trial (0.8 g carbohydrate*kg(‐)(1)*h(‐)(1))
Number of subjects: 8
Study: 8804876

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 6 months (n = 26)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 12 months (n = 34)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 12 months
Number of subjects: 60
Study: 1473321

Group type: EXPERIMENTAL
Intervention: Total breast-fed for at least 2 months
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Total breast-fed for at least 3 months
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed for at least 2 months
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed for at least 3 months
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Supplementary milk feeding begun at younger than 2 months
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Supplementary milk feeding begun at younger than 3 months
Number of subjects: 426
Study: 6380886

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 0

Group type: COMPARATOR
Intervention: meglumine iothalamate
Number of subjects: 0
Study: 31128228

Group type: EXPERIMENTAL
Intervention: Elevated ANP, BNP, or Pro‐BNP (cutoffs of >77, 100, and 900 pg/mL, respectively)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: BNP or Pro‐BNP
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Elevated ANP alone
Number of subjects: 97
Study: 28181844

Group type: EXPERIMENTAL
Intervention: New model of care (transprofessional role intervention)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study: 25417174

Group type: EXPERIMENTAL
Intervention: BEAT Cancer intervention
Number of subjects: 222
Study: 23841266

Group type: EXPERIMENTAL
Intervention: Guiling pa'an granule (GPG)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 21740238

Group type: EXPERIMENTAL
Intervention: Sof‐Lex aluminum oxide disc technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carbide bur finishing and Astrobrush polishing technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mylar matrix strips (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nanofilled composite (Filtek Z350)
Number of subjects: 60
Study: 19178965

Group type: EXPERIMENTAL
Intervention: CKD-DM
Number of subjects: 987

Group type: COMPARATOR
Intervention: CKD-only
Number of subjects: 987
Study: 16484991

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (75% VO2max, 3 times/week, 40 min/session for 6 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 31
Study: 12460129

Group type: EXPERIMENTAL
Intervention: Subtyping classifications based on gender, onset age, family history, externalizing disorders, internalizing disorders, and temperament.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Externalizing disorders, onset age, difficult temperament, and internalizing disorders.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months.
Number of subjects: 600
Study: 11072435

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch (Nicotrol)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 21-mg nicotine patch (Nicoderm)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both nicotine patches (Nicotrol and Nicoderm)
Number of subjects: 27
Study: 7540147

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (recombinant human granulocyte-macrophage colony-stimulating factor)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional chemotherapy (historical control group)
Number of subjects: 18
Study: 2025787

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment for 12 months
Number of subjects: 0
Study: 7031725

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3
Study: 6617110

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-spironolactone combination (25 mg B.I.D.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydrochlorothiazide-spironolactone combination (50 mg O.I.D.)
Number of subjects: 80
Study: 30022362

Group type: EXPERIMENTAL
Intervention: IV paracetamol 1000 mg in 100 ml solution (Group P)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg in 100 ml saline (Group I)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (Group C, 100 ml saline solution)
Number of subjects: 150
Study: 27677474

Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Plasmakinetic bipolar resection of the prostate (PKRP)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both procedures (ThuLEP and PKRP)
Number of subjects: 158
Study: 25046946

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) 50 microg, thrice per week for 24 weeks
Number of subjects: 193

Group type: COMPARATOR
Intervention: Xiaoyao Powder (XYP) combined with Interferon-alpha (IFN-alpha)
Number of subjects: 193
Study: 22682610

Group type: EXPERIMENTAL
Intervention: Fast-walking with smaller walk ratio (shorter steps, faster cadence)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Change to fast-walking with greater reduction in walk ratio (smaller increase in step length, larger increase in cadence)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Fastest quarter of gait speed during fast-walking
Number of subjects: 176
Study: 20647098

Group type: EXPERIMENTAL
Intervention: F file for 30 seconds
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EndoActivator system for 30 seconds
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation for 30 seconds
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% NaOCl irrigation for 30 seconds
Number of subjects: 40
Study: 18848553

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every other week
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg weekly
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: adalimumab combined (every other week and weekly)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: adalimumab every other week
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: adalimumab weekly
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: adalimumab combined
Number of subjects: 778

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 778
Study: 16038684

Group type: EXPERIMENTAL
Intervention: NK1 antagonist GR205171 (5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 12871686

Group type: EXPERIMENTAL
Intervention: Nicorandil (80 g/kg intravenous injection 5 min before ballooning)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 44
Study: 10475141

Group type: EXPERIMENTAL
Intervention: Clinda‐saar 600 (test preparation, 600 mg clindamycin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sobelin 300 (reference preparation, 300 mg clindamycin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 20
Study: 8870155

Group type: EXPERIMENTAL
Intervention: Proposed alternative procedure to the two-sided test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-sided test
Number of subjects: 0
Study: 1831340

Group type: EXPERIMENTAL
Intervention: Single-dose intravenous administration of CI-898 at 15 mg/m2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5-day intravenous administration of CI-898 starting at 10 mg/m2/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5-day intravenous administration of CI-898
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Single treatment of CI-898
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5-day treatment of CI-898
Number of subjects: 22
Study: 7043711

Group type: EXPERIMENTAL
Intervention: Thymopoietin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Levamisole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 36
Study: 30348586

Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 29901443

Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus‐eluting vascular scaffolds (BVS)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Drug‐eluting stents with bioabsorbable polymers (BP‐DES)
Number of subjects: 95
Study: 27598678

Group type: EXPERIMENTAL
Intervention: BDP/FF/GB (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg, glycopyrronium bromide 12.5 μg)
Number of subjects: 1368

Group type: COMPARATOR
Intervention: BDP/FF (beclometasone dipropionate 100 μg, formoterol fumarate 6 μg)
Number of subjects: 1368
Study: 24535621

Group type: EXPERIMENTAL
Intervention: LMWH‐s group (standard LMWH program, initiated 12 hours after wound closure)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: LMWH‐p group (delayed LMWH, initiated 24 hours after wound closure)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: LMWH‐s group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: LMWH‐p group
Number of subjects: 210
Study: 22515897

Group type: EXPERIMENTAL
Intervention: NovaMin paste treatment for 5 minutes (Group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (0.5 w, 10 Hz, and 50 mJ) (Group B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NovaMin followed by Nd:YAG laser (Group C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser followed by NovaMin (Group D)
Number of subjects: 48
Study: 20560802

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily for a maximum of 4 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (pain-relieving therapy only)
Number of subjects: 88
Study: 17697874

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 3 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Pioglitazone 45 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15578172

Group type: EXPERIMENTAL
Intervention: S‐omeprazole (20 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R‐omeprazole (20 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Racemic omeprazole (20 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: S‐omeprazole (40 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R‐omeprazole (40 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Racemic omeprazole (40 mg)
Number of subjects: 24
Study: 12731719

Group type: EXPERIMENTAL
Intervention: Incentive group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9933654

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP at a dose of 37 MBq/kg (group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP at a dose of 18.5 MBq/kg (group II)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Analgesics
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Karnofsky score (KS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Breast cancer subgroup
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: White blood cell and platelet counts
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Liver function tests
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 105
Study: 7476067

Group type: EXPERIMENTAL
Intervention: Accommodating resistance device (ARD) training: 3-5 sets of 10 maximal concentric actions.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Weight resistance device (WRD) training: 3-5 sets of 8-12 coupled eccentric/concentric actions to volitional failure (8-12 RM).
Number of subjects: 12
Study: 2105373

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 10
Study: 6777315

Group type: EXPERIMENTAL
Intervention: Systemic penicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31781933

Group type: EXPERIMENTAL
Intervention: Partial enteral nutrition (PEN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Exclusive enteral nutrition (EEN)
Number of subjects: 25
Study: 31184255

Group type: EXPERIMENTAL
Intervention: Web-based training (WBT)
Number of subjects: 11293

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system (CCDSS)
Number of subjects: 11293

Group type: EXPERIMENTAL
Intervention: CCDSS and WBT (BOTH)
Number of subjects: 11293

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 11293

Group type: EXPERIMENTAL
Intervention: Overall vaccination rate
Number of subjects: 11293
Study: 26603219

Group type: EXPERIMENTAL
Intervention: Hollyhock leaf compress combined with warm and cold compress
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine interventions and warm compress before nursing and cold compress after nursing
Number of subjects: 40
Study: 25389218

Group type: EXPERIMENTAL
Intervention: LSD-assisted psychotherapy
Number of subjects: 10
Study: 23533289

Group type: EXPERIMENTAL
Intervention: 3D IW fast SE
Number of subjects: 100

Group type: COMPARATOR
Intervention: 3D balanced FFE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2D fast SE
Number of subjects: 100
Study: 21627397

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-overweight children
Number of subjects: 89
Study: 18435693

Group type: EXPERIMENTAL
Intervention: 3-h recovery training (REC)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1-h active recovery
Number of subjects: 11
Study: 16506459

Group type: EXPERIMENTAL
Intervention: Iliac crest autograft (ICAG) fusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rectangular titanium cage (RTC) fusion
Number of subjects: 100
Study: 12690546

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4.5 g every 8 h)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g once daily plus gentamicin 5 mg/kg once daily)
Number of subjects: 130
Study: 10854015

Group type: EXPERIMENTAL
Intervention: Sprint interval running programme (n = 12)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Continuous cycle ergometer programme (n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 39
Study: 9176069

Group type: EXPERIMENTAL
Intervention: Fat (10% Intralipid)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23
Study: 1489202

Group type: EXPERIMENTAL
Intervention: 1-hour infusions of amphotericin B (AMB) at doses ranging from 0.27 to 0.89 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1-hour infusions of amphotericin B (AMB)
Number of subjects: 27
Study: 3156798

Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29973601

Group type: EXPERIMENTAL
Intervention: Consistent word list condition
Number of subjects: 240

Group type: COMPARATOR
Intervention: Randomized word list condition
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Within-subject word list condition
Number of subjects: 240
Study: 26372517

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12 (BB-12) administered twice a day (daily dose of BB-12 10 billion colony-forming units) until the age of 2 years.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 109
Study: 25981123

Group type: EXPERIMENTAL
Intervention: Insulin glargine (±glulisine)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Premixed insulin
Number of subjects: 923
Study: 23036264

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo-CPAP
Number of subjects: 51
Study: 21765220

Group type: EXPERIMENTAL
Intervention: Hip strengthening and movement education program 3 times per week for 6 weeks, including single-leg squat training with neuromuscular reeducation.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention, maintained current running distance).
Number of subjects: 20
Study: 19332365

Group type: EXPERIMENTAL
Intervention: Take Charge of Your Life (TCYL) program
Number of subjects: 19329

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19329
Study: 16707077

Group type: EXPERIMENTAL
Intervention: Glycerol trinitrate (GTN) patches
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard beta2 agonist
Number of subjects: 156
Study: 15265423

Group type: EXPERIMENTAL
Intervention: Triple therapy with omeperazole, clarithromycin (CLA), and amoxycillin (AMO) for one week (CLA group)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Triple therapy with omeperazole, metronidazole (MET), and amoxycillin (AMO) for two weeks (MET group)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Re-treatment with CLA triple therapy for one week after failure of MET therapy
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Re-treatment with increased doses of CLA and longer treatment course after failure of CLA therapy
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Tetra therapy with omeperazole, colloidal bismuth subcitrate (CBS), furazolidone (FUR), and AMO after failure of re-treatment
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CLA triple therapy for children who were Hp eradicated and followed for 3 years
Number of subjects: 192
Study: 11471613

Group type: EXPERIMENTAL
Intervention: Diluted gadolinium chelate (0.1 mmol/kg BW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Undiluted gadolinium chelate (0.1 mmol/kg BW)
Number of subjects: 20
Study: 9306935

Group type: EXPERIMENTAL
Intervention: CHROMagar Candida (CA)
Number of subjects: 1784

Group type: COMPARATOR
Intervention: Sabouraud dextrose agar (SDA)
Number of subjects: 1784
Study: 8028874

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Medications with hyaluronidase
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 2605440

Group type: EXPERIMENTAL
Intervention: Test A (exercise at 70% VO2 max)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Test B (exercise at fixed workload of 140 W)
Number of subjects: 9
Study: 817384

Group type: EXPERIMENTAL
Intervention: 2% solution of sodium cromoglycate (S.C.G.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30946888

Group type: EXPERIMENTAL
Intervention: PDS 10 mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 40 mg/ml
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml
Number of subjects: 220

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 220
Study: 29165105

Group type: EXPERIMENTAL
Intervention: TTM-based educational program including motivational interviewing, a booklet, and daily SMS.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 104
Study: 25467995

Group type: EXPERIMENTAL
Intervention: Unilateral core training for eight weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 16
Study: 25268241

Group type: EXPERIMENTAL
Intervention: Hand hygiene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hand hygiene plus face masks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22210302

Group type: EXPERIMENTAL
Intervention: 6-month treadmill training program
Number of subjects: 64

Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 64
Study: 20806131

Group type: EXPERIMENTAL
Intervention: Operated without pretreatment (intervention arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiation therapy with subsequent surgery (control arm)
Number of subjects: 0
Study: 19046107

Group type: EXPERIMENTAL
Intervention: Anastrozole (upfront)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (5-year regimen)
Number of subjects: 0
Study: 16401152

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied at 100% of motor threshold, frequency of 10 Hz, 40 trains at 5 seconds per train (2000 pulses per session), sessions averaged 1 to 2 per week for 6 months to 6 years
Number of subjects: 10
Study: 12566906

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 10,000 U thrice weekly s.c.
Number of subjects: 144

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 144
Study: 10392416

Group type: EXPERIMENTAL
Intervention: Botulinum‐A toxin (2 units per kilogram)
Number of subjects: 10
Study: 9078647

Group type: EXPERIMENTAL
Intervention: Active dentifrice and oral rinse containing sanguinaria extract and zinc chloride
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo dentifrice and oral rinse
Number of subjects: 34
Study: 8103272

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (8% w/v) with penetration enhancers (propylene glycol 18% and azone 2%)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle comprising olive oil with penetration enhancers
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A (8% w/v)
Number of subjects: 5